Original Article

You have free access to this content

Dynamics and management of cytopenias associated with dasatinib therapy in patients with chronic myeloid leukemia in chronic phase after imatinib failure

  1. Alfonso Quintás-Cardama MD1,
  2. Fabio Pires De Souza Santos MD1,
  3. Hagop Kantarjian MD1,
  4. Susan O'Brien MD1,
  5. Stefan Faderl MD1,
  6. Ahmed Awais MD2,
  7. Gautam Borthakur MD1,
  8. Jorge Cortes MD1,†,*

Article first published online: 10 JUN 2009

DOI: 10.1002/cncr.24432

Issue

Cancer

Cancer

Volume 115, Issue 17, pages 3935–3943, 1 September 2009

Additional Information

How to Cite

Quintás-Cardama, A., De Souza Santos, F. P., Kantarjian, H., O'Brien, S., Faderl, S., Awais, A., Borthakur, G. and Cortes, J. (2009), Dynamics and management of cytopenias associated with dasatinib therapy in patients with chronic myeloid leukemia in chronic phase after imatinib failure. Cancer, 115: 3935–3943. doi: 10.1002/cncr.24432

Author Information

  1. 1

    Department of Leukemia, The University of Texas M. D. Anderson Cancer Center, Houston, Texas

  2. 2

    Department of Internal Medicine, Memorial Hermann Hospital, The University of Texas, Houston, Texas

  1. †

    Fax: (713) 794-4297

*Department of Leukemia, The University of Texas M. D. Anderson Cancer Center, Unit 428, 1515 Holcombe Boulevard, Houston, TX 77030

Publication History

  1. Issue published online: 20 AUG 2009
  2. Article first published online: 10 JUN 2009
  3. Manuscript Accepted: 22 JAN 2009
  4. Manuscript Revised: 15 JAN 2009
  5. Manuscript Received: 1 OCT 2008

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (160K)

References

  • 1
    Lombardo LJ, Lee FY, Chen P, et al. Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J Med Chem. 2004; 47: 6658-6661.
  • 2
    Talpaz M, Shah NP, Kantarjian H, et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med. 2006; 354: 2531-2541.
  • 3
    Baccarani M, Rosti G, Saglio G, et al. Dasatinib time to and durability of major and complete cytogenetic response (MCyR and CCyR) in patients with chronic myeloid leukemia in chronic phase (CML-CP) [abstract]. Blood. 2008; 112. Abstract 450.
  • 4
    Quintas-Cardama A, Kantarjian H, O'Brien S, et al. Granulocyte-colony-stimulating factor (filgrastim) may overcome imatinib-induced neutropenia in patients with chronic-phase chronic myelogenous leukemia. Cancer. 2004; 100: 2592-2597.
    Direct Link:
  • 5
    Ault P, Kantarjian H, Welch MA, Giles F, Rios MB, Cortes J. Interleukin 11 may improve thrombocytopenia associated with imatinib mesylate therapy in chronic myelogenous leukemia. Leuk Res. 2004; 28: 613-618.
  • 6
    Cortes J, O'Brien S, Quintas A, et al. Erythropoietin is effective in improving the anemia induced by imatinib mesylate therapy in patients with chronic myeloid leukemia in chronic phase. Cancer. 2004; 100: 2396-2402.
    Direct Link:
  • 7
    Azam M, Latek RR, Daley GQ. Mechanisms of autoinhibition and STI-571/imatinib resistance revealed by mutagenesis of BCR-ABL. Cell. 2003; 112: 831-843.
  • 8
    Godwin JE, Kopecky KJ, Head DR, et al. A double-blind placebo-controlled trial of granulocyte colony-stimulating factor in elderly patients with previously untreated acute myeloid leukemia: a Southwest oncology group study. Blood. 1998; 91: 3607-3615.
  • 9
    Kantarjian H, Sawyers C, Hochhaus A, et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med. 2002; 346: 645-652.
  • 10
    Druker BJ, Guilhot F, O'Brien SG, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006; 355: 2408-2417.
  • 11
    Mauro M, Baccarani M, Cervantes F, et al. Dasatinib 2-year efficacy in patients with chronic-phase chronic myelogenous leukemia (CML-CP) with resistance or intolerance to imatinib (START-C). [abstract]. Proc Am Soc Clin Oncol. 2008; 26( May 20 suppl. Abstract 7009.
  • 12
    Shah N, Kim DW, Kantarjian H, et al. Dasatinib dose-optimization in chronic phase chronic myeloid leukemia (CML-CP): 2-year data from CA180–034 show equivalent long-term efficacy and improved safety with 100 mg once daily dose [abstract]. Blood. 2008; 112. Abstract 3225.
  • 13
    Druker BJ, Tamura S, Buchdunger E, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med. 1996; 2: 561-566.
  • 14
    Shah NP, Tran C, Lee FY, Chen P, Norris D, Sawyers CL. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science. 2004; 305: 399-401.
  • 15
    Sneed TB, Kantarjian HM, Talpaz M, et al. The significance of myelosuppression during therapy with imatinib mesylate in patients with chronic myelogenous leukemia in chronic phase. Cancer. 2004; 100: 116-121.
    Direct Link:
  • 16
    Marin D, Marktel S, Bua M, et al. Prognostic factors for patients with chronic myeloid leukaemia in chronic phase treated with imatinib mesylate after failure of interferon alfa. Leukemia. 2003; 17: 1448-1453.
  • 17
    Marin D, Marktel S, Foot N, Bua M, Goldman JM, Apperley JF. Granulocyte colony-stimulating factor reverses cytopenia and may permit cytogenetic responses in patients with chronic myeloid leukemia treated with imatinib mesylate. Haematologica. 2003; 88: 227-229.
  • 18
    Zaucha JM, Wyrowinska E, Prejzner W, Calbecka M, Hellmann A. Imatinib-associated neutropenia may not be overcome by filgrastim treatment in patients with blastic phase of chronic myeloid leukaemia. Clin Lab Haematol. 2006; 28: 208-210.
    Direct Link:
  • 19
    Heim D, Ebnother M, Meyer-Monard S, et al. G-CSF for imatinib-induced neutropenia. Leukemia. 2003; 17: 805-807.
  • 20
    Weisberg E, Catley L, Wright RD, et al. Beneficial effects of combining nilotinib and imatinib in preclinical models of BCR-ABL+ leukemias. Blood. 2007; 109: 2112-2120.
  • 21
    Khuri FR. Weighing the hazards of erythropoiesis stimulation in patients with cancer. N Engl J Med. 2007; 356: 2445-2448.
View Full Article (HTML) Get PDF (160K)